CSPC PHARMA (01093.HK): SYS6088 Phase I/II trial starts
- The product is a recombinant humanised tri-specific antibody targeting PD1, VEGFA and CTLA4, delivering a triple anti-tumour effect by restoring T-cell killing, inhibiting angiogenesis and expanding T cells.
- The Group received the Drug Clinical Trial Approval Notice in October 2026; the study evaluates safety, tolerability, PK profile and preliminary anti-tumour efficacy.
NewTimeSpace News: On 3 November 2026, CSPC Pharmaceutical Group Limited (stock code: 01093) voluntarily announced that the Phase I/II trial (SYS6088-001) of its SYS6088 Injection for advanced solid tumours has started at its first study centre in China. The product is a recombinant humanised tri-specific antibody targeting PD1, VEGFA and CTLA4. It restores T-cell killing, inhibits angiogenesis and expands T cells for a triple anti-tumour effect; Fc modification lowers toxicity risk and extends half-life.
The Group received the Drug Clinical Trial Approval Notice from the National Medical Products Administration in October 2026 and started a Phase I trial after approval. The Phase I/II trial now started is a first-in-human study evaluating safety, tolerability, pharmacokinetic profile and preliminary anti-tumour efficacy in patients with advanced solid tumours. Recruitment and screening are being actively advanced.
- CSPC PHARMA (01093.HK): SYH2072 Phase II trial starts
- CSPC PHARMA (01093.HK): SYS6057 RSV vaccine Phase I begins
- CSPC PHARMA (01093.HK): SYS6052 shingles vaccine trial starts
- CSPC PHARMA (01093.HK): Starts Phase I/II Trial of SYS6043 in China
- CSPC PHARMA (01093.HK) starts Phase I trial of SYS6077 injection, an off-the-shelf mRNA cancer vaccine
